Technologies Landscape, Trends and Prospects 2013-2024

World Newswire Discover of Incredible General Assembly in Immunicum AB (publ) Push Release 21 December

World Newswire

Discover of Incredible General Assembly in Immunicum AB (publ)

Push Release 21 December 2020 Notice of Incredible Normal Meeting in Immunicum AB (publ) The shareholders of Immunicum AB (publ) (the ”Company”), reg. no 556629-1786, are hereby invited to an Extraordinary Normal Meeting on Friday, January 22, 2021 at 13:00 at IVA Konferenscenter at Grev Turegatan 16 Stockholm. Registration for the meeting will commence at 12:30. NOTIFICATIONShareholders who desire to attend the conference shall: be recorded in the share sign-up preserved by Euroclear Sweden AB on the record day of Thursday, January 14, 2021, and not later than on Monday, January 18, 2021 have notified their attendance and any advisors to the Enterprise either in composing by using letter to Immunicum AB (publ), “General meeting”, Östermalmstorg 5, SE-114 42 Stockholm or by e-mail to [email protected] The notification shall contain total title, personalized/company id range, deal with, daytime phone amount and, when relevant, facts about deputies, proxies and advisors. The quantity of advisors can be at most two. In buy to aid registration for the assembly, the notification really should, when applicable, be accompanied by powers of legal professional, registration certificates and other paperwork of authority. Particular information received from the share register maintained by Euroclear Sweden AB, the discover and attendance at the assembly and info concerning deputies, proxies and advisors will be made use of for registration, planning of the voting list for the conference and, when applicable, the minutes from the conference. The individual info is dealt with in accordance with the General Safety Regulation (Regulation (EU) 2016/679 of the European Parliament and of the Council). For total facts regarding how the private data is handled, please refer to: https://www.euroclear.com/dam/ESw/Lawful/Privateness-notice-bolagsstammor-engelska.pdf NOMINEE REGISTERED SHARESShareholders who have experienced their shares registered in the identify of a nominee should, in buy to be entitled to take part at the conference, ask for non permanent registration in the transcription of the share sign-up preserved by Euroclear Sweden AB (so-named voting rights registration). The shareholder ought to notify the nominee hereof effectively in advance of Monday, January 18, 2021, at which time these kinds of registration shall have been made. PROXISShareholders represented by a proxy shall concern a energy of attorney which shall be dated and signed by the shareholder. If issued by a authorized entity, the power of lawyer shall be accompanied by a qualified duplicate of the certificate of registration of the lawful entity or, if this kind of document does not exist, of a corresponding doc of authority. The initial variation of the ability of lawyer shall also be introduced at the meeting. Shareholders who do not would like to show up at the assembly in individual can issue a ability of attorney to a proxy to workout their voting rights. The electric power of legal professional could be presented to the chairman of the meeting, for case in point, or one more particular person the shareholder knows will attend the meeting. If the ability of attorney is issued to the chairman of the conference, the electric power of lawyer need to involve voting directions, so the chairman of the conference is aware of how to vote on the several determination points. If the electric power of lawyer does not include things like voting instructions, the chairman will not be equipped to symbolize the shareholder at the conference. The power of legal professional ought to contain voting guidelines even in other cases. Copies of pertinent authorisation files have to also be combined with the power of legal professional as described in the recognize to the conference. The Organization presents a electrical power of legal professional sort and a blank voting instruction form to the shareholders, which will be accessible at the Company’s head business office or on the Company’s internet site https://immunicum.se/traders/corporate-governance/general-meeting/ no later on than 3 weeks just before the assembly. Training OF VOTING Legal rights BY MAILThe Board of Administrators of the Enterprise has determined that shareholders of the Enterprise at the conference shall be ready to exercising their voting rights by mail and e-mail in accordance with Part 3 of the Swedish Act (2020:198) on short-term exceptions to aid the execution of general meetings in organizations and other associations. Shareholders who want to workout their voting rights by mail must submit the postal voting sort to the Organization in accordance with the instructions given on the kind. PROPOSED AGENDA Opening of the conference and election of chairman of the meeting.Preparation and approval of the voting listing.Presentation and acceptance of the agenda.Election of a single or two people to check the minutes.Willpower as to irrespective of whether the conference has been duly convened.Election of Board of Directors and approval of remuneration to the board.Closing of the assembly. Product 1. Election of a chairman of the meetingThe Board of Directors proposes that attorney Mats Dahlberg from Advokatfirman Delphi is elected as chairman of the assembly. Merchandise 6. Election of Board of Administrators and approval of remuneration to the boardVan Herk Investments B.V. (“Van Herk”), symbolizing around 43 % of the full selection of shares and votes in the Company, proposes that the Board of Directors shall be composed of 8 (8) ordinary board users devoid of deputies. For the time period until the close of next once-a-year common conference, Van Herk proposes that Andrea van Elsas and Dharminder Chahal shall be elected as new board associates. Latest board customers Michael Oredsson, Steven Glazer, Charlotte Edenius, Christine Lind, Sven Andreasson and Helén Tuvesson are proposed to continue to be as board associates. Michael Oredsson is proposed to stay as Chairman of the Board of Directors. Van Herk proposes that Andrea van Elsas and Dharminder Chahal shall obtain the identical remuneration as the other board users in the Business, i.e. SEK 150,000 on an once-a-year foundation. The remuneration shall be modified professional rata dependent on the time from their election as board users up until the Annual Typical Assembly 2021. Brief description of proposed new board customers: Andrea van ElsasAndrea van Elsas was born in 1966 and retains a Ph.D. in Immunology and Oncology from University of Leiden and an M.S. in Molecular and Mobile Biology from College of Amsterdam. Andrea van Elsas is currently a enterprise lover with Third Rock Ventures and serves on the Scientific Advisory boards of Lava Therapeutics (chair), InteRNA Systems and the Supervisory Board of DCPrime. He has formerly served as Main Scientific Officer at Aduro Biotech, subsequent the acquisition of BioNovion, a organization he co-established in 2011, and held a variety of positions at Organon (acquired by Schering-Plough and later on by Merck) in Oss, The Netherlands, and Cambridge, Massachusetts. Though performing for Organon and Schering-Plough, Andrea Van Elsas directed the immuno-oncology portfolio and led the anti-PD1 plan that later on turned recognised as pembrolizumab. As a postdoctoral researcher, Andrea labored in the lab of 2018 Nobel Laureate Jim Allison at the University of California, Berkeley and is a co-inventor on the original anti-CTLA-4 patents that shaped the basis for the progress of ipilimumab, the 1st checkpoint inhibitor accredited in 2011 by the Fda for the therapy of melanoma. Andrea van Elsas does not have any shares in Immunicum. Dharminder ChahalDharminder Chahal was born in 1976 and holds a master’s degree in Organization Economics from Erasmus College Rotterdam and a master’s degree cum laude in Aerospace Engineering from Delft College of Technological know-how. Dharminder Chahal is CEO and co-founder of SkylineDx, a firm centered in Rotterdam, The Netherlands, producing diagnostic exams in oncology. He is also owner and handling director of Exponential BV in which ability he functions as specialist to Van Herk Investments, and is a board member of BioInvent, Ceradis, Medis Clinical Imaging, Sensara and Vitalnext as nicely as advisory board member of BioGeneration Ventures II, Thuja Money Fund I and Gilde Healthcare Resources II and III. Dharminder Chahal has formerly held a variety of positions in financial investment banking and asset administration, together with at Kempen & Co and Robeco. Dharminder Chahal has created an intensive network in the international daily life science marketplace and a strong observe report in immediate involvement of complicated corporate transactions such as the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, the sale of deVGen to Syngenta and the sale of Ablynx to Sanofi. As a board member or advisor, he has been and still is energetic for numerous European organizations in the industry of lifetime sciences. Dharminder Chahal owns 1,323,073 shares in Immunicum, which are the shares he gained as section of payment for his minority shares in DCPrime B.V. SHAREHOLDERS’ Correct TO Ask for INFORMATIONPursuant to Chapter 7 Area 32 of the Swedish Organizations Act, the Board of Directors and the Controlling Director shall, if any shareholder so requests and the Board of Directors deems that it can be performed with no sizeable harm to the Enterprise, offer facts at the common meeting relating to circumstances which may impact the evaluation of a make any difference on the agenda. Number OF SHARES AND VOTES IN THE COMPANYAt the time of the issuing of this detect the registered full range of shares and votes in the Corporation total to 92,257,531. Only 1 course of shares exist and the Corporation has no holding of have shares. The Business has an ongoing registration of 73,909,635 new shares. The Company’s evaluation is that at the time of the normal meeting the shares will be registered, whereby the overall amount of registered shares and votes in the Business will then volume to 166,167,166. DOCUMENTSProposals for resolutions and other documents are obtainable at the Company’s office on Östermalmstorg 5, Stockholm and on the Company’s web page, www.immunicum.com, not later than 3 weeks prior to the meeting, and will be sent to the shareholders who so ask for and supply their e-mail or postal address. All of the documents will be current at the typical meeting. Be sure to notice that this is a translation for info reasons only. In the occasion of any discrepancies in between the Swedish and English variations, the Swedish edition shall prevail. The details in this push release is data that Immunicum AB (publ) is obliged to disclose pursuant to Nasdaq Stockholm’s Rule Ebook for Issuers. The info was launched for general public disclosure by way of the make contact with person in depth under on 21 December 2020 at 4:05 pm CET. For much more data, remember to contact: Michael Oredsson, Chairman of the Board of DirectorsTelephone: +46 () 70 718 89 30E-mail: [email protected] ABOUT IMMUNICUM AB (PUBL) Immunicum is creating a distinctive immuno-oncology solution via the improvement of allogeneic, off-the-shelf mobile-based therapies. Our purpose is to enhance survival results and quality of existence by priming the patient’s have immune technique to battle cancer. The Company’s guide item ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the possible to grow to be a backbone component of present day cancer mixture treatments in a variety of reliable tumor indications. Immunicum has evaluated ilixadencel in many clinical trials including the not long ago accomplished exploratory Phase II MERECA review in kidney cancer and the Corporation is relocating toward late-phase scientific development. Founded and centered in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment

20201221_Immunicum_Notice of EGM_ENG_Final